Top

Published in:

01-09-2018 | Clinical Study

¹⁸F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy

Authors: Bogdana Suchorska, Marcus Unterrainer, Annamaria Biczok, Marketa Sosnova, Robert Forbrig, Peter Bartenstein, Jörg-Christian Tonn, Nathalie Lisa Albert, Friedrich-Wilhelm Kreth

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

Background

Monitoring treatment response after chemotherapy of gadolinium-(Gd)-negative gliomas is challenging as conventional MRI often indicates no radiological changes. We hypothesize that ¹⁸F-FET-PET can be used as a biomarker for response assessment in Gd-negative gliomas undergoing chemotherapy.

Methods

Sixty-one patients harboring Gd-negative WHO grade II or III glioma receiving alkylating agents (temozolomide or CCNU/procarbacine) were included. All patients underwent MRI and ¹⁸F-FET-PET before chemotherapy and 6 months later. We calculated T₂-volume, ¹⁸F-FET-PET based biological tumour volume (BTV) and maximal tumour-to-brain ratio (TBR_max). Moreover, dynamic PET acquisition was performed using time-activity-curves (TACs) analysis. For MRI-based response assessment, RANO criteria for low-grade glioma were used. For ¹⁸F-FET-PET, following classification scheme was tested: responsive disease (RD) when a decrease in either BTV ≥ 25% and/or TBR_max ≥ 10% occurred, an increase in BTV ≥ 25% and/or TBR_max increase > 10% characterized progressive disease (PD), minor changes ± 25% for BTV and ± 10% for TBR_max were regarded as stable disease (SD). Post-chemotherapy survival (PCS) and time-to-treatment failure (TTF) were calculated using the Kaplan–Meier method.

Results

¹⁸F-FET-PET based response has shown patients with RD to have the longest TTF time (78.5 vs 24.6 vs 24.1 months, p = 0.001), while there was no significant difference between patients with a SD and PD. A comparable pattern was observed for PCS (p < 0.001). T₂-volume based assessment was not associated with outcome.

Conclusion

¹⁸F-FET-PET is a promising biomarker for early response assessment in Gd-negative gliomas undergoing chemotherapy. It might be helpful for a timely adjustment of potentially ineffective treatment concepts and overcomes limitations of conventional structural imaging.

Available only for authorised users

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W, European Association for Neuro-Oncology Task Force on Gliomas (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315–e329. https://doi.org/10.1016/S1470-2045(17)30194-8 CrossRefPubMed

van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583–593. https://doi.org/10.1016/S1470-2045(11)70057-2 CrossRefPubMed

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougere C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-oncology 18:1199–1208. https://doi.org/10.1093/neuonc/now058 CrossRefPubMedPubMedCentral

Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bartschi E, Buettner UW, Roelcke U (2009) Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 95:87–93. https://doi.org/10.1007/s11060-009-9896-2 CrossRefPubMed

Roelcke U, Wyss MT, Nowosielski M, Ruda R, Roth P, Hofer S, Galldiks N, Crippa F, Weller M, Soffietti R (2016) Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-oncology 18:744–751. https://doi.org/10.1093/neuonc/nov282 CrossRefPubMed

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4 CrossRefPubMedPubMedCentral

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumour group study 26951. J Clin Oncol 31:344–350. https://doi.org/10.1200/JCO.2012.43.2229 CrossRefPubMed

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343. https://doi.org/10.1200/JCO.2012.43.2674 CrossRefPubMed

10.

Vesper J, Graf E, Wille C, Tilgner J, Trippel M, Nikkhah G, Ostertag C (2009) Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumours. BMC Neurol 9:33. https://doi.org/10.1186/1471-2377-9-33 CrossRefPubMedPubMedCentral

11.

Webre C, Shonka N, Smith L, Liu D, De Groot J (2015) PC or PCV, that is the question: primary anaplastic oligodendroglial tumours treated with procarbazine and CCNU with and without vincristine. Anticancer Res 35:5467–5472PubMed

12.

Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464–1470. https://doi.org/10.1007/s00259-004-1590-1 CrossRefPubMed

13.

Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39:1021–1029. https://doi.org/10.1007/s00259-012-2109-9 CrossRefPubMed

14.

Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Popperl G, Kreth FW, la Fougere C, Weller M, Tonn JC, German Glioma N (2015) Biological tumour volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 84:710–719. https://doi.org/10.1212/WNL.0000000000001262 CrossRefPubMed

15.

Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte K, Kaiser H, Filss C, Fink G, Coenen H, Eble M, Piroth M (2012) Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI. J Nucl Med 53:1048–1057CrossRefPubMed

16.

Engel J (1993) Surgical treatment of the epilepsies. Raven Press, New York

17.

Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A (2005) Molecular genetic analysis of oligodendroglial tumours. J Neuropathol Exp Neurol 64:10–14CrossRefPubMed

18.

Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, Tonn JC, Kretzschmar HA, Kreth FW (2009) Novel molecular stereotactic biopsy procedures reveal intratumoural homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol 68:1219–1228. https://doi.org/10.1097/NEN.0b013e3181bee1f1 CrossRefPubMed

19.

Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC, Kretzschmar HA (2007) Intratumoural homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121:2458–2464. https://doi.org/10.1002/ijc.23020 CrossRefPubMed

20.

van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145CrossRefPubMed

21.

Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, Erdem Z, Shah NJ, Fink GR, Coenen HH, Langen KJ (2013) Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med 54:2046–2054. https://doi.org/10.2967/jnumed.113.123836 CrossRefPubMed

22.

Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen KJ (2015) The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-oncology 17:1293–1300. https://doi.org/10.1093/neuonc/nov088 CrossRefPubMedPubMedCentral

Title: 18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy
Authors: Bogdana Suchorska
Marcus Unterrainer
Annamaria Biczok
Marketa Sosnova
Robert Forbrig
Peter Bartenstein
Jörg-Christian Tonn
Nathalie Lisa Albert
Friedrich-Wilhelm Kreth
Publication date: 01-09-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2919-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Rethinking medulloblastoma from a targeted therapeutics perspective

Outcome of partially irradiated recurrent nonfunctioning pituitary macroadenoma by gamma knife radiosurgery

Pre- and early postoperative GFAP serum levels in glioma and brain metastases

G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity

Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas

Evaluation of radiation-related invasion in primary patient-derived glioma cells and validation with established cell lines: impact of different radiation qualities with differing LET